ReviewJournal of clinical medicine2022
Clinical Relevance of Drug Interactions with Cannabis: A Systematic Review.
Review in Journal of clinical medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Evidence-based consensus guidelines for the pharmacological management of substance dependence: Recommendations from the British Association for Psychopharmacology.Journal of psychopharmacology (Oxford, England) · 2026Guideline
- Evaluation of potential drug-drug interactions with medical cannabis.Clinical and translational science · 2024Pooled it
- Cannabis and Cannabinoids in Adults With Cancer: ASCO Guideline.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2024Guideline
- Systematic review of drug-drug interactions of delta-9-tetrahydrocannabinol, cannabidiol, andFrontiers in pharmacology · 2024Pooled it
- Questions on Medicines, Alcohol, and Illicit Drug Interactions in the Finnish AddictionLink Online Service: A Descriptive Analysis.Nordisk alkohol- & narkotikatidskrift : NAT · 2026Article
- Cannabinoids and drug-drug pharmacokinetic interactions: Deciphering the risks.British journal of clinical pharmacology · 2026Review
- Evaluating the use and perceptions of cannabis and vaping post-cannabis legalisation in people with cystic fibrosis and CFTR-related disorder: survey results from a large Canadian adult cystic fibrosis clinic.BMJ open respiratory research · 2025Article
- Ritual to relief: ethical frontiers in repurposing psychoactive substances.CNS spectrums · 2025Review
- Concomitant use of medical cannabis and drugs associated with risks of interaction in older patients: a longitudinal cohort study.Age and ageing · 2025Article
- Perceptions of cannabis among adults aged 60 years and older in Canada: a qualitative study.Health promotion and chronic disease prevention in Canada : research, policy and practice · 2025Article
- Drug interactions in a sample of inpatients diagnosed with cannabis use disorder.Journal of neural transmission (Vienna, Austria : 1996) · 2025Article
- Recreational drugs repurposed for medicinal use-cannabis.CNS spectrums · 2025Review
- 'In the weeds': navigating the complex concerns, challenges and choices associated with medicinal cannabis consumption for endometriosis.Reproduction & fertility · 2025Article
- An Overview of the Potential for Pharmacokinetic Interactions Between Drugs and Cannabis Products in Humans.Pharmaceutics · 2025Review
- A Joint Conversation: People With Cystic Fibrosis' Perception of Healthcare Teams' Knowledge, Comfort, and Barriers in Discussing Substance Use.Pediatric pulmonology · 2025Article
- Pharmacokinetics and Side Effects of ΔKidney international reports · 2025Article
- Cannabinoids in Chronic Pain Management: A Review of the History, Efficacy, Applications, and Risks.Biomedicines · 2025Review
- Changes in and correlates of cannabis-involved substance use treatment admissions age 50 and older, 2000-2021.Frontiers in public health · 2025Article
- Analysis of six CYP450 genetic variants regarding the response to cannabidiol combined with anticonvulsant medication in mexican patients with drug-resistant epilepsy.Frontiers in pharmacology · 2025Article
- Adverse events associated with the use of cannabis-based products in people living with cancer: a systematic scoping review.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Concomitant use of cannabis with other drugs may lead to cannabis-drug interactions, mainly due to the pharmacokinetic mechanism involving the family of CYP450 isoenzymes. This narrative systematic review aimed to systematize the available information regarding clinical relevance of cannabis-drug interactions. We utilized the PubMed/Medline database for this systematic review, using the terms drug interactions and cannabis, between June 2011 and June 2021. Articles with cannabis-drug interactions in humans, in English or Spanish, with full-text access were selected. Two researchers evaluated the article's inclusion. The level of clinical relevance was determined according to the severity and probability of the interaction. Ninety-five articles were identified and twenty-six were included. Overall, 19 pairs of drug interactions with medicinal or recreational cannabis were identified in humans. According to severity and probability, 1, 2, 12, and 4 pairs of cannabis-drug interactions were classified at levels 1 (very high risk), 2 (high risk), 3 (medium risk), and 5 (without risk), respectively. Cannabis-warfarin was classified at level 1, and cannabis-buprenorphine and tacrolimus at level 2. This review provides evidence for both the low probability of the occurrence of clinically relevant drug interactions and the lack of evidence regarding cannabis-drug interactions.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.